Evaluation of Lymphodepletion With ALLO-647 in Adults With R/R Large B Cell Lymphoma Receiving ALLO-501A Allogeneic CAR T Cell Therapy

NCT05714345 · clinicaltrials.gov ↗

PHASE2

Phase

TERMINATED

Status

2

Enrollment

INDUSTRY

Sponsor class

Stopped Terminated early for business reasons.

Conditions

Relapsed/Refractory Large B Cell Lymphoma

Interventions

BIOLOGICAL: ALLO-647
DRUG: Fludarabine
DRUG: Cyclophosphamide
GENETIC: ALLO-501A

Sponsor

Allogene Therapeutics